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Abstract
Commercial uses of bioactive peptides require low cost, effective methods for their produc-
tion. We developed a new carrier protein for high yield production of recombinant peptides
in Escherichia coli very well suited for the production of toxic peptides like antimicrobial pep-
tides. GKY20, a short antimicrobial peptide derived from the C-terminus of human thrombin,
was fused to the C-terminus of Onconase, a small ribonuclease (104 amino acids), which
efficiently drove the peptide into inclusion bodies with very high expression levels (about
200–250 mg/L). After purification of the fusion protein by immobilized metal ion affinity chro-
matography, peptide was obtained by chemical cleavage in diluted acetic acid of an acid
labile Asp-Pro sequence with more than 95% efficiency. To improve peptide purification,
Onconase was mutated to eliminate all acid labile sequences thus reducing the release of
unwanted peptides during the acid cleavage. Mutations were chosen to preserve the differ-
ential solubility of Onconase as function of pH, which allows its selective precipitation at
neutral pH after the cleavage. The improved carrier allowed the production of 15–18 mg of
recombinant peptide per liter of culture with 96–98% purity without the need of further chro-
matographic steps after the acid cleavage. The antimicrobial activity of the recombinant
peptide, with an additional proline at the N-terminus, was tested on Gram-negative and
Gram-positive strains and was found to be identical to that measured for synthetic GKY20.
This finding suggests that N-terminal proline residue does not change the antimicrobial
properties of recombinant (P)GKY20. The improved carrier, which does not contain cyste-
ine and methionine residues, Asp-Pro and Asn-Gly sequences, is well suited for the produc-
tion of peptides using any of the most popular chemical cleavage methods.
PLOS ONE | DOI:10.1371/journal.pone.0146552 January 25, 2016 1 / 23
a11111
OPEN ACCESS
Citation: Pane K, Durante L, Pizzo E, Varcamonti M,
Zanfardino A, Sgambati V, et al. (2016) Rational
Design of a Carrier Protein for the Production of
Recombinant Toxic Peptides in Escherichia coli.
PLoS ONE 11(1): e0146552. doi:10.1371/journal.
pone.0146552
Editor: Mark J van Raaij, Centro Nacional de
Biotecnologia - CSIC / CIF Q2818002D, SPAIN
Received: September 22, 2015
Accepted: December 19, 2015
Published: January 25, 2016
Copyright: © 2016 Pane et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by grants FFC#9/
2012, FFC#11/2013, and FFC#12/2014 from “Italian
Cystic Fibrosis Research Foundation” (http://www.
fibrosicisticaricerca.it) and “Programma F.A.R.O IV
tornata” (CUP: E68C12000260003) funded by Polo
delle Scienze e Tecnologie, Università di Napoli
Federico II. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Introduction
Peptides of length between five and fifty residues have many applications in research, diagnostic,
medicine (e.g. antimicrobial [1, 2], anti-inflammatory [3], anti-cancer [4] and cell penetrating
peptides [5] etc.) and industry (e.g. metal surface-binding [6] and graphite-binding peptides [7]).
Solid phase chemical synthesis is well suited to obtain small amounts of peptides but it could be
rather expensive when peptides longer than 30 amino acids or high quantities of peptide are
required. On the other hand, recombinant production of peptides [8–11] entails several difficul-
ties. For example, expression of some peptides can be toxic for the host and several peptides are
very sensitive to proteases thus leading to low yields. These difficulties can be circumvented by
fusing the desired peptide to a carrier protein that can protect peptides from proteases, neutralize
possible toxic effects and provide a convenient route for their purification. However, also fusion
protein strategy has two main drawbacks. Firstly, the fusion protein has to be cleaved and pep-
tide needs to be separated from the carrier, secondly, the desired peptide usually represents just a
small percentage of the purified fusion protein. As for the cleavage of the peptide, it can be
released from the fusion protein by enzymatic or chemical cleavage at a site suitably introduced
at the carrier-peptide junction ([10] and references therein). The efficiency and specificity of the
cleavage is the main bottleneck of fused peptide production. Usually enzymatic proteolysis by
factor Xa [12, 13], enterokinase [14] and thrombin [15, 16], the most used enzymes, is less effi-
cient than chemical cleavage [17–19]. The lower efficiency of enzymatic methods is generally
attributed to unfavorable surrounding residues and/or to steric hindrance which make the cleav-
age sites not fully accessible. Furthermore, enzymes usually require non-denaturing reaction
conditions to work properly. Thus, enzymatic proteolysis cannot be used when the fusion pro-
tein is partly or completely insoluble. On the other hand, the most popular cleavage reagents,
like cyanogen bromide (CNBr), formic acid and hydroxylamine, which cleave Met-X, Asp-Pro
and Asn-Gly peptide bonds [10, 20, 21], respectively, often produce unwanted cleavages and
side-chain modifications due to the harsh reaction conditions needed for the cleavage [22–28].
For example, cleavage of Asp-Pro sequences, usually performed at 60°C in 50–70% formic acid,
often results in unspecific hydrolysis, formylation and oxidation reactions of side chains [28].
Here, we describe the rational development of a new carrier protein for high yield produc-
tion of recombinant peptides in Escherichia coli very well suited for toxic peptides like antimi-
crobial peptides [10]. The denatured form of Onconase (ONC), a RNase from Rana pipiens
[29], was chosen as starting point to design the carrier protein. ONC is a very well suited part-
ner for several reasons: (i) it can be expressed at very high levels in inclusion bodies (about
200–250 mg/L in terrific broth); (ii) usually no soluble ONC can be detected in growth cultures
thus minimizing the risk of toxic effects of the ONC-peptide fusion proteins; (iii) it is a very
small protein (104 aa) thus allowing high yields of the peptides after the cleavage; (iv) the solu-
bility of denatured Onconase is pH dependent—the denatured protein is soluble only at pH
<4 –thus allowing the purification of peptides soluble at pH 7 by selective precipitation of the
carrier. Moreover, ONC does not contain Asp-Pro and Asn-Gly sequences and the mutant
(M23L)-ONC [30] does not contain internal methionine residues, therefore it is compatible
with all common chemical cleavage strategies.
Starting from mutant (M23L)-ONC we have developed an improved carrier protein bearing
15 mutations and an improved cleavage procedure of Asp-Pro peptide bonds that does not
require formic acid.
We tested the efficiency of our strategy by producing GKY20, a short cationic antimicrobial
peptide derived from the C-terminus of human thrombin [31]. Like other similar antimicrobial
peptides, GKY20 is endowed with broad spectrum antimicrobial activity being active both on
Gram-positive and Gram-negative bacteria. Its bactericidal activity has been attributed to its
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capacity to induce membrane lysis. Moreover, it shows potent anti-inflammatory activity due
to its ability to bind LPS thus inhibiting macrophage responses to these components of the
outer membrane [32]. Noteworthy, GKY20 is active on different strains of E. coli with a mini-
mal inhibitory concentration (MIC) lower than 10 μM [33]. In spite of this high toxicity we
were able to prepare recombinant GKY20 in E. coli with final yield of about 15–20 mg per L of
culture and purity higher than 96–98%.
Results and Discussion
Expression vector design: ONC-(P)GKY20 fusion protein
Native ONC is a small protein (104 aa) stabilized by four disulfide bridges. When expressed in
E. coli, wild type ONC and its mutants are produced at high yield as inclusion bodies [29, 30].
We have previously shown that once extracted by denaturation using guanidine chloride and
dialyzed in acetic acid 0.1 M the denatured form is very soluble, whereas at pH 7 it is prone to
aggregation and efficient renaturation can only be achieved by a special procedure based on
reversible blocking of cysteine residues [29]. In order to use denatured ONC as carrier for the
production of recombinant peptide GKY20, we prepared a chimeric open reading frame
including codons 1–103 of (M23L)-ONC [34], five codons coding for a linker sequence
(GTGDP) containing the formic acid cleavable aspartyl-prolyl dipeptide, and a sequence cod-
ing for GKY20 (Fig 1A and S1 File, panel A). This sequence was obtained by changing six
codons in the human coding sequence to better match E. coli codon usage (S1 File, panel C). It
should be reminded that ONC does not contain Asp-Pro and Asn-Gly sequences (S1 File,
panel A). Moreover, mutant (M23L)-ONC does not contain any internal methionine residue.
Thus, mutant (M23L)-ONC represents an ideal scaffold for the chimeric construct because it is
not cleaved by the usual chemical cleavage strategies.
The linker sequence was chosen both to introduce a flexible region into the chimeric protein
between the ONCmoiety and GKY20 and to introduce two restriction enzyme sites, KpnI
(codons coding for amino acids GT) and BamHI (codons coding for amino acids GDP). More-
over, C-terminal cysteine of the ONC moiety (Cys104) was deleted to avoid the presence of an
oxidation prone residue near to the cleavage site. The synthetic construct and the correspond-
ing recombinant protein were named ONC-(P)GKY20 to underline that, by acid cleavage, the
recombinant protein releases peptide (P)GKY20 i.e. peptide GKY20 with an additional proline
at the N-terminus. The construct was cloned into pET22b(+) plasmid between NdeI and SacI
restriction sites (Fig 1A) and expressed into BL21(DE3) E. coli cells. Expression of recombinant
protein was obtained as described in Materials and Methods.
SDS-PAGE analysis of induced cultures (Fig 2) showed high expression levels of ONC-(P)
GKY20 (200–250 mg/L) as inclusion bodies. The recombinant protein was partially purified by
denaturation of the inclusion bodies and dialysis in 0.1 M acetic acid pH 2.9 that causes the
precipitation of most of the E. coli proteins. As shown in Fig 2 (lane 4), after dialysis the soluble
fraction contained less than 15–20% of E. coli proteins as determined by SDS-PAGE densitom-
etry scan. This sample was used to optimize the acidic cleavage of the DP sequence as described
in the next section.
Chemical cleavage optimization of aspartyl-prolyl bonds in ONC-(P)
GKY20 fusion protein
The cleavage of Asp-Pro sequences is usually performed at temperatures in the range 55–80°C
in 50–75% formic acid. However, these reaction conditions often produce unwanted side reac-
tions like formylation and unspecific hydrolysis [22–28].
Design of a Carrier Protein for Recombinant Peptide Production
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In order to find less harsh cleavage conditions, thermal incubations of ONC-(P)GKY20
fusion protein were carried out in different acid solutions: 50%, 60% or 70% formic acid (Fig
3A), 0.1 M acetic acid (pH 2.9), 0.1 M acetic acid adjusted at pH 2.0 with HCl (Fig 3B). Samples
were incubated at 50° or 60°C for 3, 6, 9, 15 or 24 h. With the exception of 0.1 M acetic acid pH
Fig 1. Schematic representation of expression vectors and recombinant proteins. Fusion proteins without (A) and with (B) His6-Tag. The main
restriction enzyme sites,NdeI, EcoRI, KpnI, BamHI and SacI were reported. MCS: multicloning site. Onconase: carrier protein (grey). Linker: DNA sequence
coding for GTGDP amino acid residues (red). GKY20: human Thrombin derived peptide (blue).
doi:10.1371/journal.pone.0146552.g001
Fig 2. Protein expression. SDS-PAGE analysis of ONC-(P)GKY20 and ONC-DCless-H6-(P)GKY20 fusion
proteins. Lane M1: marker (14.3 kDa). Lanes 1–4, ONC-(P)GKY20 protein: lane 1, cell lysate of induced
culture; lane 2, insoluble fraction after cell lysis; lane 3, soluble fraction after cell lysis; lane 4, purified ONC-
(P)GKY20 recombinant protein after dialysis against 0.1 M acetic acid. Lane M2: marker (8-12-20-30-45-60-
100-220 kDa proteins). Lanes 5–8, ONC-DCless-H6-(P)GKY20 fusion protein: lane 5, cell lysate of induced
culture; lane 6, insoluble fraction after cell lysis; lane 7, soluble fraction after cell lysis; lane 8, inclusion bodies
after triton/urea wash.
doi:10.1371/journal.pone.0146552.g002
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2.9 (Fig 3B), all the acidic solutions resulted in the efficient hydrolysis (>90%) of the recombi-
nant fusion protein by incubating samples at 60°C for times 15 h, but with a significant dif-
ference: in the case of the acetic acid solution at pH 2.0, a specific cleavage pattern with the
formation of six discrete polypeptide bands was visible on SDS-PAGE (Fig 3B), whereas in the
case of formic acid, in addition to the bands observed in the case of the acetic acid/HCl hydro-
lysis, a smear was clearly evident suggesting the occurrence of unspecific cleavages (Fig 3A).
This experiment indicated that it is possible to cleave the recombinant protein without
using high concentrations of organic acids, but unfortunately they also revealed two unex-
pected problems: i) mild acidic hydrolysis cleaved ONC-(P)GKY20 in several fragments (Fig
3B) in spite of the fact that it contains a single Asp-Pro sequence between ONC and GKY20; ii)
some E. coli proteins, present in small amount as contaminants in the inclusion bodies, also
Fig 3. Hydrolysis pattern of ONC-(P)GKY20 protein. Samples were cleaved at acid pH for 24 h at 60°C
and analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lanes 1, 5: purified fusion protein. (A) ONC-
(P)GKY20 protein hydrolyzed in 50% (lane 2), 60% (lane 3) e 70% (lane 4) formic acid (60°C, 24 h). (B) ONC-
(P)GKY20 protein hydrolyzed in 0.1 M acetic acid, pH 2.9, (lane 6) and in 0.1 M acetic acid adjusted at pH 2.0
with HCl (lane 7); the N—terminal sequences of the fragments obtained by hydrolysis of ONC-(P)GKY20
fusion protein (lane 6) were as follow: fragment 1, PGK [(P)GKY20 peptide)] and MQD (N-terminal peptide,
less represented); fragment 2, X(Cys)NVT (D67-C68 cleavage site); fragment 3, X(Cys)NVT (D67-C68
cleavage site) and MQD (N-terminal peptide, less represented); fragment 4, X(Cys)DNI (D18-C19 cleavage
site); fragments 5 and 6, MQD (N-terminal region) which represent the carrier protein and uncleaved fusion
protein respectively. (C) Amino acid sequence of ONC-(P)GKY20 fusion protein; the main cleavage sites are
underlined.
doi:10.1371/journal.pone.0146552.g003
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underwent cleavage releasing shorter fragments as evidenced by the disappearance of high
molecular weight bands.
N-terminal sequencing of the fragments separated by SDS-PAGE (Fig 3B), allowed to iden-
tify three main sites of cleavage in the fusion protein. In addition to the expected cleavage at
the Asp-Pro sequence in the linker sequence, which releases the desired peptide (P)GKY20,
two unexpected sites of hydrolysis were identified: Asp18-Cys19 and Asp67-Cys68. An incom-
plete hydrolysis at these sites accounts for the six bands observed in the SDS-PAGE (Fig 3B).
Band 1 contained (P)GKY20 and a peptide corresponding to the N-terminus of ONC (includ-
ing initial methionine). Intermediate bands were due to fragments starting at Cys19 and Cys68.
Bands 5 and 6 contained fragments starting at the N-terminal sequence of ONC. On the basis
of their migration they are likely the uncleaved fusion protein (band 6) and the ONC moiety
resulting from a single cleavage at the Asp-Pro sequence (band 5). To the best of our knowledge
this is the first report of efficient acid induced cleavage at Asp-Cys sequences.
On the basis of these observations we concluded that the acid cleavage with 0.1 M acetic
acid pH 2.0 of ONC-(P)GKY20 fusion protein could not be used to obtain pure (P)GKY20
peptide. Thus, we decided to try to improve the carrier sequence (i) to overcome the undesired
cleavages we have observed, and (ii) to avoid the formation of the short fragments derived
from the hydrolysis of contaminant E. coli proteins.
Improvement of the carrier sequence: first generation mutants
Improvement of the Onconase carrier was performed by a trial and error procedure. For sim-
plicity in Table 1 several different versions of the carrier are divided into "first generation” and
“second generation” fusion proteins.
The mutations introduced into the first generation proteins were chosen mainly to remove
the unexpected Asp-Cys cleavage sites and to obtain a high purity fusion protein in order to
reduce the release of unwanted peptides during the acid cleavage step from contaminant E. coli
proteins.
As for unexpected Asp-Cys cleavage sites, sequences Asp-Cys were mutated to Asp-Tyr and
Glu-Tyr. Mutations were chosen to preserve the propensity of denatured ONC to form inclu-
sion bodies and to aggregate at pH 7. Since protein solubility and propensity to form aggre-
gates, like inclusion bodies, are generally related to net charge, hydrophobicity and to the
presence of amphipatic secondary structures [35, 36], the amino acid substitutions were chosen
in order to preserve these properties. Therefore, aspartic acid residues were replaced with glu-
tamic acid residues in order to preserve the net charge. Cysteine residues were replaced with
tyrosine residues as in several hydrophobicity scales these two residues show very similar
hydrophobicity scores [37]. Moreover, the replacement of Asp-Cys with Glu-Tyr allows to
keep unchanged secondary structure propensity since the replacement of aspartate with gluta-
mate decreases the preference for loop structures, whereas the replacement of cysteine with
tyrosine increases the preference for loop structures. Furthermore, the mutant bearing the two
Glu-Tyr sequences was also prepared with a six histidine-tag sequence (H6) inserted between
the ONC moiety and the flexible linker GTGDP (Fig 1B).
All the recombinant fusion proteins showed high expression levels as inclusion bodies, thus
indicating that the chosen mutations did not interfere with the formation of inclusion bodies
(Fig 4).
When Asp-Cys sequences were changed to Asp-Tyr [ONC(YY)-(P)GKY20 fusion protein]
or to Glu-Tyr [ONC(EYEY)-(P)GKY20 fusion protein] a drastic reduction of unwanted acid
cleavage in 0.1 M acetic acid pH 2.0 at 60°C for 24 h was observed (Fig 5A and 5B, respec-
tively). The SDS-PAGE analysis of the cleavage products of ONC(YY)-(P)GKY20 and ONC
Design of a Carrier Protein for Recombinant Peptide Production
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(EYEY)-(P)GKY20 was similar but not identical. In particular only ONC(YY)-(P)GKY20
reproducibly showed a smear corresponding to bands 2 and 3 in the analysis of ONC-(P)
GKY20 (Fig 5A), thus suggesting that only mutation Asp-Cys to Glu-Tyr abolished the cleav-
age at the bond Asp67-Cys68. On the contrary both mutants showed two close bands (Fig 5A
and 5B, respectively) whose migration is similar to that of band 4, attributed to the cleavage at
the bond Asp18-Cys19. As mentioned in the previous section the disappearance of high molec-
ular weight bands suggested the release of unwanted peptides produced during the acid cleav-
age step from contaminant E. coli proteins (Fig 5B). Therefore, we decided to increase the
purity of the protein sample subjected to acid hydrolysis by the addition of a H6 tag sequence
to the chimeric proteins. ONC(EYEY)-H6-(P)GKY20 mutant was produced and purified as
Table 1. Expression vectors, fusion proteins and peptides.
Expression vectors Fusion proteins Linker and Cleavage site Peptides Peptide (N-terminal end)
First generation fusion proteins
pET22b(+)/ONC-(P)GKY20 ONC-(P)GKY20a GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(YY)-(P)GKY20 ONC(YY)-(P)GKY20b GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(EYEY)-(P)GKY20 ONC(EYEY)-(P)GKY20c GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC(EYEY)-H6-(P)GKY20 ONC(EYEY)-H6-(P)GKY20d GTGDP GKY.. (P)GKY20 P-GKY. . .
Second generation fusion proteins
pET22b(+)/ONC-DCless-H6-(P)GKY20 ONC-DCless-H6-(P)GKY20e GTGDP GKY.. (P)GKY20 P-GKY. . .
pET22b(+)/ONC-DCless-H6-(PM)GKY20 ONC-DCless-H6-(PM)GKY20e GTGDPM GKY.. (PM)GKY20 PM-GKY. . .
- - - GKY20 GKY. . .
a ONC: Onconase mutant-M23L,C104 delete;
b ONC(YY): Onconase mutant-M23L,C19Y,C68Y,C104 delete;
c ONC(EYEY): Onconase mutant-M23L,D18E,C19Y,D67E,C68Y,C104 delete;
d ONC(EYEY)-H6: Onconase mutant-M23L,D18E,C19Y,D67E,C68Y,C104 delete; H6: Hexa-histidine tag at the C-terminal side of the onconase carrier.
e ONC-DCless-H6: Onconase mutant-M23L,D2E,D16E,D18E,C19Y,D20E,C30Y,D32E,C48L,D67E,C68Y,C75Y,C87I,C90I,C104 delete; H6: Hexa-
histidine tag at the C-terminal side of the onconase carrier.
doi:10.1371/journal.pone.0146552.t001
Fig 4. Protein expression of first generation mutants. (A) SDS-PAGE analysis of insoluble (lanes 1, 3)
and soluble (lanes 2, 4) fractions after cell lysis of ONC(YY)-(P)GKY20 and ONC(EYEY)-(P)GKY20 fusion
proteins, respectively. (B) SDS-PAGE analysis of soluble (lane 5) and insoluble (lane 6) fractions after cell
lysis of ONC(EYEY)-H6-(P)GKY20 fusion protein. Lane M: marker (14.3 kDa).
doi:10.1371/journal.pone.0146552.g004
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described in Materials and Methods. As it is shown in Fig 5, the addition of the H6 tag signifi-
cantly improved the purity of the chimeric protein from about 80% (Fig 5B) to more than 96–
98% as determined by SDS-PAGE densitometry scan (Fig 5C), with a recovery of about 95% of
the total fusion protein. Purified ONC(EYEY)-H6-(P)GKY20 was subjected to acid cleavage in
0.1 M acetic acid pH 2.0 at 60°C for 24 h as described above. SDS-PAGE analysis of ONC
(EYEY)-H6-(P)GKY20 acid cleavage mixtures (Fig 5C) still evidenced the presence of the two
faint bands observed in the case of ONC(EYEY)-(P)GKY20 thus demonstrating that these
bands derive from cleavage of the fusion proteins and not from the contaminants. Taken
together, our data suggested that, in addition to the bonds Asp18-Cys19 and Asp67-Cys68, fur-
ther acid labile bonds are present in Onconase. Studies on protein and peptide aging have dem-
onstrated that all Asp-X bonds can undergo spontaneous hydrolysis, even if at a lesser extent
than the Asp-Pro bond [38–40]. For example, Joshi and co-workers [39, 40] demonstrated that
at acidic pH glucagon undergoes degradation due to hydrolysis at the Asp9-Tyr10 and Asp15--
Ser16 bonds and at a lesser extent at the Asp21-Phe22 bond. These findings are in agreement
with our conclusion that Asp67-Tyr68 in ONC(YY)-(P)GKY20 fusion protein contributes to
the release of ONC derived fragments and suggest that one or more of the additional Asp-X
sequences present in the ONC moiety (Asp2-Trp3, Asp16-Val17, Asp20-Asn21 and
Asp30-Lys31) could be sensitive to acid hydrolysis. In particular one or both the two close
bands observed in the hydrolysis products of ONC(YY)-(P)GKY20 and ONC(EYEY)-(P)
GKY20 fusion protein could be tentatively attributed to cleavage at the Asp16-Val17 and/or
Asp20-Asn21 and/or Asp-30-Lys31 bonds.
Improvement of the carrier sequence: second generation mutants
Mutations introduced into the second generation protein ONC-DCless-H6-(P)GKY20 were
chosen to remove all the potential unwanted cleavage sites and to reduce the possibility of
unwanted formation of intra-chain disulfides without changing the expression level of the
fusion protein, its propensity to form inclusion bodies in E. coli and the propensity of dena-
tured Onconase to form large aggregates at pH higher than 5 as this feature is very useful to
Fig 5. Comparison of hydrolysis patterns of first and second generation mutants.Chemical cleavage was carried out in 0.1 M acetic acid adjusted at
pH 2.0 with HCl (60°C, 24 h). Samples were analyzed on 20% SDS-PAGE. Lane M1: markers (13.8 kDa, 11.8 kDa). Lane M2: RK-16 peptide (1961.25 Da).
Lane M3: marker (14.3 kDa). (A) ONC(YY)-(P)GKY20 purified fusion protein (lane 1) and hydrolyzed protein (lanes 2–4, three independent experiments).
ONC-(P)GKY20 purified protein (lane 5) and cleaved protein (lane 6). (B, C, D) ONC(EYEY)-(P)GKY20, ONC(EYEY)-H6-(P)GKY20 and ONC-DCless-H6-
(P)GKY20 purified fusion proteins (lanes 7, 9, 11, respectively), and hydrolyzed proteins (lane 8, 10, 12, respectively). Onc-P: Onconase/Peptide fusion
protein; Onc: Onconase carrier; P: (P)GKY20 peptide. Fragments obtained by hydrolysis of ONC-(P)GKY20 fusion protein (B, lane 6) are numbered as in Fig
3.
doi:10.1371/journal.pone.0146552.g005
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remove the carrier after the acid cleavage by means of a simple centrifugation step (as described
below). To this aim, as discussed for the first generation mutants, the four remaining aspartic
acid residues in the ONC moiety were replaced with glutamic acid residues to preserve the
charge and all the cysteine residues were mutated to other residues of similar or higher hydro-
phobicity chosen on the basis of the secondary structure of native ONC. Accordingly, the single
cysteine residue (Cys48) present within alpha helix 3 (S2 File) was replaced with a leucine resi-
due (a “helix-preferring” residue). The two cysteine residues located in beta strands (Cys87 and
Cys90) were replaced with isoleucine (a “beta-preferring” residue). Finally, two cysteine resi-
dues located in loops (Cys30 and Cys75) were replaced with tyrosine residues. It should be
noted that the mutation of cysteine to leucine or isoleucine increases significantly the hydro-
phobicity and, likely, the propensity of the protein to aggregate.
ONC-DCless-H6-(P)GKY20 (Table 1), was produced in the form of inclusion bodies with a
yield similar or higher than that observed for ONC-(P)GKY20 (Fig 2), thus demonstrating that
the amino acid substitutions into the carrier sequence did not influence protein expression lev-
els. After purification on Ni-sepharose, ONC-DCless-H6-(P)GKY20 showed about 98% purity
as determined by SDS-PAGE densitometry scan (Fig 5D), with a recovery of about 95%.
After cleavage in 0.1 M acetic acid adjusted at pH 2.0, at 60°C for 24 h, SDS-PAGE analysis
allowed to estimate 95% efficiency in the release of (P)GKY20. It is worth noting that no
unwanted cleavage was observed, thus confirming that aspartic acid residues were responsible for
the low efficiency cleavages observed in the case of ONC(EYEY)-H6-(P)GKY20 protein (Fig 5D).
Adjusting the pH to 7.2–7.4 with NH3 and incubating the mixture at 28°C for 16 h the
uncleaved ONC-DCless-H6-(P)GKY20 and ONC-DCless-H6 proteins formed macroscopic
insoluble aggregates which were completely removed by centrifugation (Fig 6). Peptide (P)
GKY20 was recovered in the soluble fraction, lyophilized and used for the characterization
described below without any further purification step. Mass spectrometry analysis (Fig 7A),
confirmed the peptide identity and showed that no modified form (e.g. oxidized or formylated
peptides) was present in the sample.
Final purity of (P)GKY20 peptide, as determined by reverse phase chromatography (Fig
7B), typically ranged from 95% to 99%.
The optimized procedure allowed the purification of about 10–11 mg of peptide starting
from 100 mg of purified fusion protein with 70–75% recovery efficiency (actual milligrams of
peptide/expected milligrams of peptide) with respect to the theoretical amount of peptide in
the fusion protein.
Cleavage by cyanogen bromide of ONC-DCless-H6-(PM)GKY20 fusion
protein
Starting from ONC-DCless-H6-(P)GKY20 we prepared mutant ONC-DCless-H6-(PM)
GKY20. In this fusion protein the additional mutation, a single amino acid insertion, is located
in the peptide moiety rather than in the ONCmoiety which is identical to that of ONC-DC-
less-H6-(P)GKY20. By acid hydrolysis it releases peptide (PM)GKY20 carrying two additional
residues at the N-terminus. However, as ONC-DCless-H6 does not contain methionine resi-
dues, ONC-DCless-H6-(PM)GKY20 fusion protein can also be cleaved using CNBr to release
the peptide GKY20 which does not have any additional residue at the N-terminus.
By acid cleavage ONC-DCless-H6-(PM)GKY20 provided results identical to those obtained
in the case of ONC-DCless-H6-(P)GKY20 (Fig 8), thus showing that the additional methionine
residue following the Asp-Pro sequence has no influence on the acid cleavage efficiency.
ONC-DCless-H6-(PM)GKY20 fusion protein was also cleaved by using CNBr in 0.2 M HCl
as described in details in the Material and Methods section. As shown in Fig 9 the efficiency of
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cleavage (about 80%, as determined by SDS-PAGE densitometry scan) was only slightly lower
than that obtained with acid hydrolysis, thus demonstrating that ONC-DCless-H6-(PM)
GKY20 fusion protein can be effectively cleaved by both chemical methods.
Antimicrobial activity
In order to verify if recombinant peptide (P)GKY20 possesses antimicrobial activity compara-
ble to that of a synthetic GKY20, both peptides were tested by plate viable-count assay on a
Gram-positive strain, Staphylococcus aureus ATCC 6538P, and a Gram-negative strain, Pseu-
domonas aeruginosa KK27 [a clinical strain isolated from a cystic fibrosis patient kindly pro-
vided by Dr. Alessandra Bragonzi (San Raffaele Hospital, Milan)]. As shown in Fig 10, the
antimicrobial activity of (P)GKY20 was identical to that measured for synthetic GKY20.
Moreover, to further investigate if N-terminal proline of (P)GKY20 affected the potency of
the peptide, we determined, by broth microdilution method, the MIC values (the lowest con-
centration of antimicrobial agent at which no growth is observed) of the two peptides. As
shown in Table 2 and Fig 11, peptides exhibited the same MIC values towards several Gram-
positive and Gram-negative strains. These data are very close to those determined against E.
coli and S. aureus strains for synthetic C-terminal human thrombin peptides [33]. Taken
together, these findings suggest that N-terminal proline residue does not change the antimicro-
bial properties of recombinant (P)GKY20.
Conclusions
Through a rational design strategy we have progressively improved the suitability of ONC as a
carrier for the production of recombinant peptides. The final version of the protein, ONC-DC-
less-H6, may likely be a very efficient carrier particularly suited for the production of peptides
expected to be very toxic for the host E. coli like antimicrobial peptides. It is expressed at high
levels (>200 mg/L) efficiently forming inclusion bodies, and thus sequestering the hosted
Fig 6. Purification of recombinant (P)GKY20 peptide.DS-PAGE (20%) analysis. Lane M: marker (14.3
kDa). Lane 1: ONC-DCless-H6-(P)GKY20 fusion protein purified by IMAC. Lane 2: cleaved fusion protein
(0.1 M acetic acid adjusted at pH 2.0 with HCl, 60°C, 24 h). Lane 3: soluble fraction after neutralization of the
cleavage reaction [(P)GKY20 peptide]. Lane 4: insoluble fraction after neutralization of the cleavage reaction
(uncleaved fusion protein and Onconase cleaved carrier). Onc-P: Onconase/Peptide fusion protein; Onc:
Onconase carrier; P: (P)GKY20 peptide.
doi:10.1371/journal.pone.0146552.g006
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peptide in an insoluble form. Once solubilized by chaotropic agents the chimeric protein can
be easily purified by Ni-chelate chromatography without the need of removing the denaturing
agent. At pH lower than 4 denatured ONC is very soluble, therefore chemical cleavage proce-
dures that require an acidic environment (e.g. cleavage of aspartyl-prolyl bonds and CNBr
cleavage) can be performed also in diluted acids such as 0.1 M acetic acid or HCl without the
need to employ high concentrations of formic acid that is often chosen for its denturing/solubi-
lizing properties [28, 41] but, as already mentioned, causes several unwanted reactions. After
the cleavage at acidic pH, the ONC moiety, ONC-DCless-H6, can be easily removed due to its
Fig 7. Characterization of purified recombinant (P)GKY20 peptide. (A) Mass spectrum of purified (P)GKY20 peptide. The measured molecular weight
(2609.47 Da) is consistent with the theoretical value (2609.1 Da). (B) Reverse-phase HPLC chromatogram recorded at 280 nm wavelength. Purified peptide
was applied to a C18 column (Jupiter 5u C18 300Å, 250 x 4.6 mm) and eluted with a linear gradient from 5% to 95% acetonitrile containing 0.05%
trifluoroacetic acid, over 60 min at flow rate of 1 mL/min.
doi:10.1371/journal.pone.0146552.g007
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Fig 8. Asp-Pro cleavage efficiency comparison of ONC-DCless-H6-(P)GKY20 and ONC-DCless-H6-
(PM)GKY20 fusion proteins. Samples were cleaved in 0.1 M acetic acid adjusted at pH 2.0 with HCl (60°C,
24 h) and analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lane 1: ONC-DCless-H6-(PM)GKY20
purified fusion protein. Lanes 2, 3: ONC-DCless-H6-(PM)GKY20 (lane 2) and ONC-DCless-H6-(P)GKY20
(lane 3) hydrolyzed proteins. Onc-P: Onconase/Peptide fusion protein; Onc: Onconase carrier; P: (P)GKY20
peptide.
doi:10.1371/journal.pone.0146552.g008
Fig 9. Cyanogen bromide cleavage of ONC-DCless-H6-(PM)GKY20 fusion protein. Samples were
analyzed on 20% SDS-PAGE. Lane M: marker (14.3 kDa). Lane 1, purified fusion protein. Lanes 2, 3:
cleaved recombinant protein in 0.2 M HCl with 100- (lane 2) and 400-fold (lane 3) molar excess of CNBr over
methionine residues. Sample were incubated in the dark at room temperature for 24 h. Onc-P: Onconase/
Peptide fusion protein; Onc: Onconase carrier; P: (P)GKY20 peptide.
doi:10.1371/journal.pone.0146552.g009
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complete insolubility at neutral pH. This feature may allow a simple and effective purification
of any peptide that is soluble at pH 7.0. Alternatively, the carrier could be removed under dena-
turing conditions by Ni-chelate chromatography as after acidic cleavage it retains the H6 tag.
Table 3 shows a comparison between our method and those reported in some recent papers
describing the production of recombinant antimicrobial peptides.
As for the cleavage of the hosted peptide, ONC-DCless-H6 is very versatile. As it does not
contain methionine residues nor Asp-Pro sequences or any other acid sensitive sequence,
Fig 10. Antibacterial activity of recombinant (P)GKY20 and synthetic GKY20 peptides. Assays were
carried out by viable-count method. (A) Staphylococcus aureus ATCC 6538P; (B) Pseudomonas aeruginosa
KK27. Dose-effect curves: 0.1–0.5-1-2-3 μM final concentrations were tested. Error bars are standard
deviations. Black circles: synthetic GKY20. White circles: (P)GKY20.
doi:10.1371/journal.pone.0146552.g010
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hosted peptides may be released either by CNBr or by acidic cleavage. Furthermore, as the
ONC scaffold does not contain any cysteine residues, peptides may also be released by using
2-nitro-5-thiocyanatobenzoic acid, a reagent that very specifically modify thiols causing the
cleavage of X-Cys bonds [20, 28], by replacing the DP or DPM sequences at the end of the flex-
ible linker with a cysteine.
Our strategy, due to its simplicity and limited costs, is also suited for the scale up and could




Expression host strain E. coli BL21(DE3) and plasmid pET22b(+) were purchased from Nova-
gen (San Diego, CA, USA). E. coli strain TOP10F’ was obtained from Invitrogen (San Diego,
CA, USA). QIAprep spin miniprep kit was from Qiagen (Germantown, MD, USA). Wizard SV
Gel and PCR Clean-Up DNA Purification System for elution of DNA fragments from agarose
gel was purchased from Promega (Madison, WI, USA). Enzymes and other reagents for DNA
manipulation were from New England Biolabs (Ipswich, MA, USA). Ni Sepharose™ 6 Fast
Flow was from GE Healthcare (Uppsala, Sweden). The GKY20 peptide was chemically synthe-
sized by INBIOS s.r.l. (University of Naples, Italy). Difco Nutrient Broth was from Becton-
Dickenson (Franklin Lakes, NJ). All other chemicals were from Sigma-Aldrich (Milano, Italy).
General procedures
Bacterial cultures, plasmid purifications and DNA manipulation were carried out according to
Sambrook [42]. DNA sequences and oligonucleotide synthesis were performed by Eurofins
MWGOperon service (Ebersberg, Germany). Sodium Dodecyl Sulphate PolyAcrylamide Gel
Electrophoresis (SDS-PAGE) was carried out according to Laemmli [43]. Gallus gallus lyso-
zyme (14.3 kDa), human pancreatic RNase A (13.8 kDa), recombinant Onconase from Rana
pipiens (11.8 kDa) and RK-16 peptide from Salmo salar Ss-RNasi 1 [44] (16 aa: RYPH-
CRYRGSPPSTRK; theoretical molecular weight, 1961.25 Da) were used as molecular markers.
When appropriate, the relative amount of bands was determined by densitometry performed
Table 2. Antibacterial activity of Thrombin derived peptides.
MIC (μM)a
(P)GKY20 GKY20
Bacterial strain Replicatesb Replicatesb
E. coli DH5α 12.5 12.5 12.5 12.5 12.5 12.5
E. coli ATCC 25922 12.5 12.5 25 12.5 12.5 25
E. coli ATCC 35218 12.5 12.5 12.5 12.5 12.5 12.5
P. aeruginosa PAO1 25 12.5 25 25 12.5 25
P. aeruginosa PA14 50 50 25 50 50 25
S. aureus ATCC 6538P 6.25 3.12 6.25 6.25 3.12 6.25
K. pneumoniae ATCC 700603 12.5 12.5 12.5 12.5 12.5 12.5
B. megaterium SF185 12.5 12.5 12.5 12.5 12.5 12.5
aAssays were carried out by broth dilution method in Nutrient Broth 0,5 X.
bReplicates were from three independent experiments.
doi:10.1371/journal.pone.0146552.t002
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using the Gel Doc™ XR system (Bio-Rad Laboratories, Inc.) equipped with the Quantity One1
Software. Protein concentration was determined by the Bradford Protein Assay (Sigma-
Aldrich, St. Louis, MO, USA) and standard curves were generated using bovine serum albumin
(BSA). Concentrations of purified fusion proteins and peptides were determined by spectro-
photometric analysis using the extinction coefficients calculated using the ProtParam tool
(accessible to the address http://web.expasy.org/protparam/) [45]. Amino-terminal sequencing
was carried out on polypeptides separated by denaturing gel electrophoresis and then electro-
blotted onto polyvinylidene difluoride (PVDF) membranes [46].
Fig 11. Inhibition growth assay of E. coliDH5α (A) and S. aureusATCC 6538P (B). Assays were carried
out by broth dilution method in Nutrient Broth 0.5x. Bacteria from overnight culture were inoculated (~5x105
CFU/mL) in the presence of different concentration of tested peptides (0.2–100 μM). After incubation at 37°C
for 16 h, the minimum inhibitory concentration (MIC) was determined as the lowest concentration showing no
visible growth. All measurements were carried out three times in independent experiments.
doi:10.1371/journal.pone.0146552.g011
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Construction of the expression vectors
DNA sequences coding for fusion proteins reported in Table 1, were obtained by chemical syn-
thesis (MWG-Biotech AG; Ebersberg, Germany) or by PCR mutagenesis.
Synthetic genes coding for recombinant proteins ONC-(P)GKY20, ONC-DCless-H6-(P)
GKY20 and ONC-DCless-H6-(PM)GKY20 (Table 1) were obtained by MWG-Biotech AG
(Ebersberg, Germany). All codons were optimized for expression in E. coli and restriction sites
Table 3. Recently published papers reporting the production of recombinant antimicrobial peptides in Escherichia coli (E.c.) or Bacillus subtilis (B.
s.).
Reference Host Carriera number
of
peptides
























































I.M.A.C. 30 mg/g of
dry cells
>95%
[53] E.c. His tagged
SUMOa
1e Soluble I.M.A.C. SUMO protease
(complete)
I.M.A.C. Not reported >95%
[54] B.s. His tagged
SUMOa
















at 25°C for 16 h
(~50%)
RP-HPLC 1.7 mg/L Not
reported










2 mg/L ~ 92%
aHis tagged ketosteroid isomerase, SUMO, CBD/Intein and thioredoxin-based methods are commercially available; here we report the most recent
applications based on these carriers.
bSequences of peptides (P)GKY20 and (PM)GKY20 are in S1 File.
cPS-Pexiganan-HH (PS-Pex-HH; PS-GIGKFLKKAKKFGKAFVKILKK-HH) and omiganan (GILRWPWWPWRRK-HHHHHH). Omiganan was expressed as
fusion protein but not further analysed.





iDialysis and lyophilization steps are not indicated.
jMeasured only for ONC-DCless-H6-(PM)GKY20.
kOnly peptide p53pAnt could be cleaved by thrombin. 80% cleavage efﬁciency was obtained by incubating for 48h the fusion protein with thrombin,
whereas, 95% efﬁciency was reached by addition of fresh enzyme and further incubation.
lCalculated from data in ﬁgure 3 of reference 4.
mAuthors state that after the selective precipitation “. . .most of the DAMP4var was removed by centrifugation (Fig 7A, lane 2), and relatively pure PS-Pex-
HH was obtained for MIC testing (Fig 7A, lane 3 and Fig 7B)”.
doi:10.1371/journal.pone.0146552.t003
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NdeI and SacI were introduced at 5’- and 3’-end of the synthetic genes, respectively, for their
cloning into pET22b(+) vector (Fig 1; S1 File).
All other DNA sequences coding for mutants reported in Table 1 were obtained by Overlap
Extension PCRMutagenesis or by PCRMutagenesis [47] using the appropriate primers and
pET22b(+)/ONC-(P)GKY20 or pET22b(+)/ONC(EYEY)-(P)GKY20 plasmids as templates. PCR
reactions were carried out using the Phusion High Fidelity DNA Polymerase (Thermo Fisher,
New England Biolabs). PCR reactions were started by preheating samples at 94°C for 2 min.
Amplifications were performed as follows: 20 cycles at 94°C for 30 s, 56°C for 30 s and 72°C for
30 s, with a final elongation stage at 72°C for 10 min. Amplified products were digested with
the appropriate restriction enzymes for their cloning into the pET22b(+) vector. E. coli strain
TOP10F’ was used for all cloning procedures.
Expression of recombinant proteins
E. coli strain BL21(DE3) was used to express recombinant proteins. Cells, transformed with
pET recombinant plasmids, were grown in 10 mL of Terrific Broth medium (TB) containing
100 μg/ml ampicillin, at 37°C up to OD600nm of 2. These cultures were used to inoculate 1 L of
TB/ampicillin medium. Glucose at final concentration of 4 g/L was added to cultures to limit
protein expression before induction with IPTG. TB medium was found to be able to induce
protein expression over the early growth phase reducing the final optical density of cultures
and therefore the recombinant protein yield [48]. Cultures were incubated at 37°C up to
OD600nm of 3.5–4. Expression of recombinant proteins was induced by addition of IPTG (iso-
propyl-β-D-thiogalactopyranoside) at a final concentration of 0.4 mM. Cells were harvested
after overnight induction by centrifugation at 8000x g for 15 min at 4°C and washed with 50
mM Tris-HCl buffer, pH 7.4. The bacterial pellet was suspended in 50 mM Tris-HCl buffer,
pH 7.4, containing 10 mM ethylenediaminetetraacetic acid (EDTA), and sonicated in a cell dis-
ruptor (10 x 1 min cycle, on ice). The suspension was then centrifuged at 18,000 x g for 60 min
at 4°C. Soluble and insoluble fractions were analyzed by SDS-PAGE. The insoluble fractions
containing the recombinant protein as inclusion bodies, were washed three times in 0.1 M
Tris-HCl buffer, pH 7.4, containing 10 mM EDTA, 2% Triton X-100 and 2 M urea, followed
by repeated washes in 0.1 M Tris-HCl buffer, pH 7.4, to eliminate traces of Triton, urea and
EDTA. This procedure eliminated several contaminant proteins and cellular debris entrapped
in inclusion body pellets.
Purification of fusion proteins
To purify fusion proteins lacking His6-Tag, a procedure was developed to obtain partially puri-
fied protein without any chromatographic step. To this purpose, 100 mg of fusion proteins
were dissolved in 10 mL of denaturing buffer (6 M guanidine/HCl in 50 mM Tris-HCl, pH 7.4)
containing 10 mM β-mercaptoethanol. Mixtures were incubated at 37°C for 3 h under nitrogen
atmosphere on a rotary shaker, and then centrifuged at 18,000 x g for 60 min at 4°C. Soluble
fractions were collected by centrifugation and acidified to pH 3.0 by adding glacial acetic acid
before extensive dialysis against 0.1 M acetic acid at 4°C. Soluble fusion proteins were separated
from insoluble E. coli proteins by centrifugation and stored at -80°C under nitrogen
atmosphere.
His6-tagged recombinant proteins were purified by immobilized metal ion affinity chroma-
tography (IMAC), using the Ni Sepharose™ 6 Fast Flow resin. 100 mg of fusion proteins were
dissolved in 10 mL of denaturing buffer containing 10 mM β-mercaptoethanol and incubated
on a rotary shaker at 37°C for 3 h under nitrogen atmosphere. Soluble fractions were collected
by centrifugation and incubated with 5 mL of Ni Sepharose™ 6 Fast Flow resin equilibrated in
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denaturing buffer. The resin was shaken at 4°C for 16 h and then collected by centrifugation.
The supernatant, containing the unbound proteins, was discarded. The resin was washed three
times with 25 ml of denaturing buffer at 4°C for 30 min and then packed in a glass column.
The fusion proteins were eluted with 20 ml of 0.1 M sodium acetate buffer, pH 5.0, containing
6 M guanidine/HCl (elution buffer). The eluate was extensively dialyzed against 0.1 M acetic
acid at 4°C. Samples were stored at -80°C under nitrogen atmosphere. Purified fusion protein
concentrations were determined by spectrophotometric analysis using the extinction coeffi-
cients calculated using the ProtParam tool [ε280 = 24,410 M
_1 cm_1; ε280 (0.1%) = 1.53].
Cleavage optimization of Asp-Pro peptide bond
Fusion proteins were cleaved by thermal incubation in acid solutions under nitrogen atmo-
sphere. To optimize chemical cleavage, formic acid and acetic acid, were tested. Purified fusion
proteins in 0.1 M acetic acid were lyophilized and suspended in i) 50%, 60% and 70% formic
acid or ii) 0.1 M acetic acid at pH 2.9 or at pH 2.0 (by addition of diluted HCl). The mixtures
were incubated for 3-6-9-15-24 h, at 37°C, 50°C and 60°C. Cleavage efficiency was analyzed by
SDS-PAGE using 20% gel. Formaldehyde was used to covalently link proteins and polypeptides
in polyacrylamide gels [49]. To this purpose, 4% formaldehyde was added to the Coomassie
Blue staining solution (0.2% Coomassie Brilliant Blue R-250, 25% isopropyl alcohol and 10%
glacial acetic acid). Percentage of cleaved protein was determined by densitometric analysis of
SDS-PAGE gels as described in “General procedures”.
Identification of polypeptides obtained by chemical cleavage was carried out by N-terminal
sequencing. Proteins and polypeptides were separated by denaturing gel electrophoresis, elec-
troblotted onto polyvinylidene difluoride (PVDF) membranes, stained by Ponceau S dye and
sequenced by the Edman method [46].
Chemical cleavage and purification of recombinant (P)GKY20 peptide
Cleavage of the peptide from fusion proteins was performed in 0.1 M acetic acid at pH 2.0,
incubating samples at 60°C for 24 h in a water bath under nitrogen atmosphere. The mixtures
were then neutralized to pH 7–7.2 by adding NH3, purged with N2 and incubated at 28°C for
16 h in a water bath. The soluble peptide was isolated from the insoluble carrier through
repeated cycles of centrifugation at 18,000 x g for 60 min at 4°C. Purified peptide was lyophi-
lized and stored at -80°C. Peptide concentrations were determined by spectrophotometric anal-
ysis using the extinction coefficients calculated using the ProtParam tool [ε280 = 8,480 M
-1 cm-
1; recombinant (P)GKY20 peptide, ε280 (0.1%) = 3.250; GKY20 peptide, ε280 (0.1%) = 3.376].
The purity of (P)GKY20 peptide was verified by SDS-PAGE and reverse-phase HPLC using
a Waters (Milford, MA, USA) HPLC system (1525 binary pump and 2996 photodiode array
detector). The column was a C18 (250 x 4,6 mm, 5μm particle size) Jupiter 5u C18 300 Å (Phe-
nomenex). The solvents were 0.05% trifluoracetic acid (TFA) in water (solvent A) and 0.05%
TFA in acetonitrile (solvent B). The column was equilibrated with 5% acetonitrile and the pep-
tide was eluted by a linear gradient ranging from 5% to 95% solvent B over 60 min, at a flow
rate of 1 ml/min. The elution was monitored at 280 nm. Purity was determined by measuring
the relative area of peaks using the Empower software (Waters, Milford, MA, USA).
The identity of the peptide was determined by mass spectrometry. Positive Reflectron
MALDI spectra were recorded on a Voyager DE STR instrument (AB Sciex, Framingham,
MA). The MALDI matrix was prepared by dissolving α-cyano-hydroxycinnamic powder in
70% acetonitrile and 30% citric acid 50 mM. Typically 1 μL of matrix was applied to the metal-
lic sample plate and 1 μL of analyte was added. The mixture thus obtained was then dried at
room temperature. Acceleration and reflector voltages were set up as follows: target voltage at
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20 kV, first grid at 65% of target voltage, delayed extraction at 400 ns to obtain the best signal-
to-noise ratios and the best possible isotopic resolution. Mass calibration was performed using
external peptide standards purchased from AB Sciex. Each spectrum represents the sum of
3,000 laser pulses from randomly chosen spots per sample position. Raw data were analyzed
using the computer software provided by the manufacturers and are reported as monoisotopic
masses.
Cyanogen bromide cleavage reaction
CNBr cleavage was performed on purified recombinant ONC-DCless-H6-(PM)GKY20 pro-
tein. Sample was lyophilized and then resuspended in 0.2 M HCl at final concentration of 1.5
mg/mL. Cleavage was started by the addition of 100- and 400-fold molar excess of CNBr (40
mg/mL in 0.2 M HCl stock solution) over methionine residues, and the mixtures were incu-
bated in the dark at room temperature for 24 h. Reaction mixtures were dried under vacuum
and washed three times in 0.1 M acetic acid to allow CNBr evaporation. Samples were resus-
pended in 0.1 M acetic acid and the efficiency of cleavage was estimated by densitometric anal-
ysis of SDS-PAGE.
Antimicrobial assay
Antibacterial activity assays were carried out by i) agar dilution plate viable-count method [44]
and ii) broth microdilution method for antimicrobial peptides [50].
Agar dilution plate viable-count method was performed as previously described [44] with
minor modifications. A single colony of Pseudomonas aeruginosa (KK27) or Staphylococcus
aureus (ATCC 6538P) was suspended in 5 mL of Luria-Bertani (LB) medium (Becton, Dickin-
son) and overnight incubated at 37°C. When the cultures reached an OD600nm of 1 unit, they
were diluted 1:100 in 20 mM sodium phosphate buffer (NaP), pH 7.0. Samples were prepared
by adding 40 μL of bacterial cells to peptides at 0.1, 0.5, 1.0, 2.0, and 3.0 μM final concentra-
tions, in 1 mL of 20 mMNaP buffer, pH 7.0. Cells incubated with antibiotic (colistin 0.01 mg/
mL and ampicillin 0.05 mg/mL) were used as positive control, whereas cells incubated without
any antibiotics or peptide were prepared as negative control. Bovine serum albumin (BSA) was
tested at the same concentration of the peptides. Samples were incubated at 37°C for 4 hours
and dilutions (1:100 and 1:1000) of all the samples were placed on LB/agar medium and incu-
bated overnight at 37°C. The following day survived cells were estimated by colonies counting
on each plate and compared with controls. All compounds were tested in triplicate experi-
ments. Standard deviations were always less than 5%.
Minimal Inhibitory Concentration (MIC) was determined by broth microdilution method
following the protocol previously described for antimicrobial peptides [50] with minor modifi-
cations. Assays were carried out in Difco Nutrient Broth composed of 0.5% beef extract (w/v),
0.05% pepton and 0.25% NaCl, using sterile 96-well polypropylene microtiter plates (cat. 3879,
Costar Corp., Cambridge, MA). Twofold serial dilutions of peptides were carried out in the test
wells to obtain concentrations ranging from 100 μM to 0.2 μM. Bacteria were inoculated from
an overnight culture at a final concentration of ~ 5x105 CFU/mL per well and incubated over-
night at 37°C. MIC value was taken as the lowest concentration at which growth was inhibited.
Three independent experiments were performed for each MIC value. Controls included the
peptide antibiotic polymyxin B and vancomycin (Sigma, St. Louis, MO). MIC values were mea-
sured on: Escherichia coli DH5α, P. aeruginosa PAO1, P. aeruginosa PA14, B.megaterium
SF185, S. aureus ATCC 6538P from our laboratory strains collection and on Escherichia coli
ATCC 25922, Escherichia coli ATCC 35218, K. pneumoniae ATCC 700603 (kindly provided by
Eliana De Gregorio, University of Naples Federico II, Italy).
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Supporting Information
S1 File. Nucleotide and amino acid sequences. (A) ONC-(P)GKY20 and (B) ONC-DCless-
H6-(P)GKY20 fusion proteins. Onconase carrier (black); peptide (blue); linker region (red
underlined); His6-Tag (green). Amino acid substitutions in ONC-DCless-H6-(P)GKY20 pro-
tein sequence (B) were highlighted: glutamate residues (red), tyrosine residues (purple), leucine
residue (light blue), isoleucine residues (orange). The main restriction enzyme sites were also
reported: NdeI (turquoise); EcoRI (yellow); KpnI (grey); BamHI (green); SacI (pink). (C)
Sequence alignment of human prothrombin gene (GenBank: M17262) segment coding for
GKY20 (black) and the manually improved sequence (blue). Mutated codons were underlined
and nucleotide substitutions were highlighted in yellow.
(DOCX)
S2 File. Onconase secondary structure. Alpha helices (h) and beta strands (e) from Onconase
crystallographic structure [PDB:1ONC] are shown below the sequence. (A) Amino acid
sequence of ONCmutant (Onconase M23L, C104 delete); (B) amino acid sequence of
ONC-DCless mutant (Onconase M23L, D2E, D16E, D18E, C19Y, D20E, C30Y, D32E, C48L,
D67E, C68Y, C75Y, C87I, C90I, C104 delete). The amino acid substitutions are pointed out:
red, D2E, D16E, D18E, D20E, D32E, D67E mutations; grey, M23L mutation; turquoise, C19Y,
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